Market Overview

UPDATE: Benchmark Raises PT to $18 on Cardiovascular Systems on Improved Visibility

Share:
Related CSII
28 Stocks Moving In Monday's Pre-Market Session
Cardiovascular Systems (CSII) Hits 52-Week High on Solid Q3
9 Stocks Steven Cohen Keeps Buying (GuruFocus)

Benchmark reiterated its Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII) and increased its price target from $13.50 to $18.

Benchmark said, "We believe that there is a significant market opportunity in the U.S. for CSII to launch their device in the coronary market during calendar Q1:14. We estimate that CSII will send their clinical data to the FDA during calendar Q1:13 and we expect regulatory approval in the U.S. and subsequent launch during calendar Q1:14. CSII did a modular design with module 1 being preclinical and module 2 being manufacturing/system quality. … Peer comparables trade at a revenue per share multiple of 3 to 5 time and, based on the improved visibility, we are moving our valuation multiple from 3 to 4 times."

Cardiovascular Systems closed at $12.22 on Monday.

Latest Ratings for CSII

DateFirmActionFromTo
Sep 2017Raymond JamesInitiates Coverage OnMarket Perform
Jun 2017Bank of AmericaDowngradesNeutralUnderperform
Aug 2016Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for CSII
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CSII)

View Comments and Join the Discussion!

Partner Center